Alpha Tau reports1H EPS (22c) vs (24c) in 1H23

As of June 30, the company had cash and cash equivalents, short-term deposits and restricted deposits in the amount of $74.1 M , compared to $84.9M at December 31, 2023. ..The Company expects that this cash balance will be sufficient to fund anticipated operations for at least two years.”While we continue to advance our ReSTART U.S. multicenter pivotal trial in recurrent cutaneous squamous cell carcinoma, the overwhelming interest from clinicians and the broader community in our ongoing internal organ trials has been fantastic,” stated Alpha Tau CEO Uzi Sofer. “We are fortunate to see such strong clinician demand for participation in clinical trials, at a time when we expect meaningful data generation, in particular with continued progress in our clinical trials in pancreatic cancer outside the U.S. as well as regulatory progress on similar trials in the U.S. We also continue to prepare for potential future product launches by advancing our commercial planning activities and solidifying our supply chain, as we have secured approvals for our new manufacturing plant in Hudson, New Hampshire and commenced renovation of the facility for our needs. Alpha Tau expects to remain adequately capitalized to support all of these programs over the coming years,” he concluded.